Edwards Lifesciences Corp 4

Daniel J. Lippis, CVP, TAVR of Edwards Lifesciences Corp (EW), exercised 619 stock options at $72.68 and sold 619 common shares at $91.70 on July 10, 2026 under a Rule 10b5-1 plan.

On July 10, 2026, Daniel J. Lippis, CVP, TAVR of Edwards Lifesciences Corp, exercised 619 employee stock options at an exercise price of $72.68 per share, acquiring 619 shares of common stock, and on the same day sold 619 shares of common stock at $91.70 per share under a Rule 10b5-1 trading plan adopted on February 13, 2026. The option exercise itself showed $0 in price on the derivative line because the economic cost is reflected in the $72.68 per share on the corresponding common stock acquisition entry, while the sale generated proceeds of approximately $56,832.30. After these transactions, Lippis’s direct ownership in Edwards Lifesciences common stock increased slightly to 40,033.9103 shares from 40,652.9103 reported in the acquisition line, with the filing noting that it reflects only the reported securities and not all beneficially owned securities.

Filing Facts

CIK

1099800

Ticker

EW

Form

4

Source Type

sec

Accession

0001225208-26-006576

Alert Tier

5